Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 6-(2-fluorophenyl)-n-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo(h)quinazolin-2-amine
2. Arq 087
1. 1234356-69-4
2. Arq-087
3. Arq087
4. Derazantinib [usan]
5. Arq 087
6. N9b0h171mj
7. (6r)-6-(2-fluorophenyl)-n-(3-{2-[(2-methoxyethyl)amino]ethyl}phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine
8. Benzo(h)quinazolin-2-amine, 6-(2-fluorophenyl)-5,6-dihydro-n-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-, (6r)-
9. Benzo[h]quinazolin-2-amine, 6-(2-fluorophenyl)-5,6-dihydro-n-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-, (6r)-
10. Derazantinib(arq-087)
11. Derazantinib [inn]
12. Derazantinib (arq 087)
13. Unii-n9b0h171mj
14. Derazantinib [who-dd]
15. Gtpl9785
16. Chembl4297187
17. Schembl13273847
18. Arq-087arq-087
19. Amy16754
20. Bcp29103
21. Ex-a1717
22. S8609
23. Who 10488
24. Akos037648596
25. Cs-7922
26. Db14889
27. Ac-30343
28. Bs-14785
29. Hy-19981
30. A16825
31. C71924
32. (6r)-6-(2-fluorophenyl)-5,6-dihydro-n-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-benzo[h]quinazolin-2-amine
33. (r)-6-(2-fluorophenyl)-n-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine
34. 1814961-15-3
| Molecular Weight | 468.6 g/mol |
|---|---|
| Molecular Formula | C29H29FN4O |
| XLogP3 | 5.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 9 |
| Exact Mass | 468.23253972 g/mol |
| Monoisotopic Mass | 468.23253972 g/mol |
| Topological Polar Surface Area | 59.1 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 638 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Derazantinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Derazantinib, including repackagers and relabelers. The FDA regulates Derazantinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Derazantinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Derazantinib supplier is an individual or a company that provides Derazantinib active pharmaceutical ingredient (API) or Derazantinib finished formulations upon request. The Derazantinib suppliers may include Derazantinib API manufacturers, exporters, distributors and traders.
Derazantinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Derazantinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Derazantinib GMP manufacturer or Derazantinib GMP API supplier for your needs.
A Derazantinib CoA (Certificate of Analysis) is a formal document that attests to Derazantinib's compliance with Derazantinib specifications and serves as a tool for batch-level quality control.
Derazantinib CoA mostly includes findings from lab analyses of a specific batch. For each Derazantinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Derazantinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Derazantinib EP), Derazantinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Derazantinib USP).
LOOKING FOR A SUPPLIER?
